(Q37693931)

22 August 2017

1 reference

title

Daptomycin: pharmacology and clinical use. (English)

1 reference

22 August 2017

1 reference

Christos Kosmidis

1

1 reference

22 August 2017

Donald P Levine

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

615-625

1 reference

Community-associated methicillin-resistant Staphylococcus aureus: a review

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Once-daily dosing in dogs optimizes daptomycin safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Resolution of persistent Pediococcus bacteremia with daptomycin treatment: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin for line-related Leuconostoc bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of Bacillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

In vitro activity of LY146032 against gram-positive bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

In vivo pharmacodynamic activity of daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Rhabdomyolysis and acute renal failure in a patient treated with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Clinical experience with daptomycin for the treatment of patients with osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Cost-Effectiveness of daptomycin versus vancomycin and gentamicin for patients with methicillin-resistant Staphylococcus aureus bacteremia and/or endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Resistance studies with daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Activity of daptomycin against gram-positive bacterial isolates from Indian medical centres (2006-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Mechanisms of resistance to daptomycin in Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598893

10.1517/14656561003598893

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference